Home
Aditum Bio

Aditum Bio Market Share Analysis for June 2026

Aditum Bio is a new model of biotech venture capital, uniquely positioned to rapidly translate scientific discoveries into innovative new medicines.

Industry: N/A

Domainaditumbio.com

Year Founded2019

Employees51 - 200

Annual Revenue--

Aditum Bio

Aditum Bio (including company regionals)

aditumbio.com

See more website traffic and engagement information

Total visits to Aditum Bio's top domains

Understand Aditum Bio market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

aditumbio.com5.5K

See more with Sales Intelligence

Avg. visit duration in Aditum Bio's top domains

Analyze Aditum Bio engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

aditumbio.com00:00:09

See more with Sales Intelligence

Avg. pageviews on Aditum Bio's top domains

See how Aditum Bio keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

aditumbio.com1.56

See more with Sales Intelligence

Aditum Bio top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Aditum Bio

These are the website technologies, by industry, used by Aditum Bio top domains

Email Services (3)

G Suite

Advertising (2)

PubMatic

Content Management System (2)

WordPress

Mobile (2)

Meta Viewport

More Technologies

8

See all

News & Signals from Aditum Bio

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAditum Bio launched Kalexo Bio on Sep 17th '25.SH) and Aditum Bio today announced the launch of Kalexo Bio, a new company formed in conjunction with an exclusive global license agreement to develop 2MW7141, a novel dual-target siRNA candidate for lipid management in patients with dyslipidemia and for the prevention of high-risk atherosclerotic cardiovascular disease (ASCVD) events.

NewsAditum Bio is developing LBL-051 on Nov 7th '24.On Nov. 7, 2024, Aditum Bio and Leads Biolabs announced that they have formed a new company, Oblenio Bio, in conjunction with an exclusive option and license agreement the companies have entered into to develop LBL-051, a first-in-class CD19xB-cell maturation antigen (BCMA)xCD3 tri-specific T-cell engager antibody, for treating autoimmune diseases.

NewsAditum Bio is developing tri-specific t-cell engager for autoimmune disorders.Aditum Bio and Leads Biolabs announce the formation of Oblenio Bio to develop a tri-specific t-cell engager for autoimmune disorders.